CCL13 and Nasal polyposis: The expression of Th2 markers, including CCL13, was not found to be altered in nasal polyposis (NP) patients receiving glucocorticoid (GC) therapy; this lack of change in expression levels may suggest that T-cell-driven NP inflammatory mediators are resistant to the effects of GC treatment (82).